Come join me dur­ing my round-the-world biotech ad­ven­ture in Oc­to­ber, with events in Lon­don and Shang­hai — plus

A few years ago I had a chance to do a half-day event in Lon­don with a top group of biotech ex­ecs, and I’ve been mean­ing to get back to the Gold­en Tri­an­gle for a re­turn event ever since.

Now, with the Great Around the Biotech World Trip I’m plan­ning for Oc­to­ber, that time has ar­rived.


On Oc­to­ber 10, I’m bring­ing to­geth­er a great group of lead­ers in the biotech com­mu­ni­ty for the first an­nu­al End­points News UK Bio­phar­ma Re­search & De­vel­op­ment Sum­mit, host­ed at the Sil­i­con Val­ley Bank au­di­to­ri­um in Lon­don. 

We’ll be cov­er­ing key is­sues like fi­nanc­ing trends, the ROI of drug de­vel­op­ment and new in­no­va­tion, and how top can­cer drug de­vel­op­ers in the coun­try are nav­i­gat­ing the huge burst of new stud­ies that has swelled the pipeline in re­cent years.

Mene Pan­ga­los

My pan­elists in­clude Mene Pan­ga­los, the EVP of In­no­v­a­tive Med­i­cines, at As­traZeneca; Tim Haines

Kate Bing­ham

from Abing­worth; Kate Bing­ham at SV Health In­vestors; John Pot­tage, CSO at Vi­iV; Nooman Haque at SVB; David Grainger at Medicxi; Jack­ie Hunter from Benev­o­len­tAI; Mike Rea from IDEA; Mal­colm Weir, CEO at Hep­tares; Niall Mar­tin, CEO from Ar­tios and David Chiswell, the leg­endary CAT co-founder who now helms Kymab.

Plus a few we have yet to name.

You can read all about the half-day agen­da here. If you want­ed me to sum up the ob­jec­tive here, I’d say I’m look­ing for a clear up­date on the Gold­en Tri­an­gle’s place in this fast-chang­ing biotech world, with in­vestors act­ing more bull­ish­ly than I’ve ever seen. And I’d like to show the bio­phar­ma world what it looks like from the per­spec­tive of some of the bright­est peo­ple in the field.

We have a lim­it­ed num­ber of seats avail­able for an event that will be record­ed for a lat­er broad­cast. And I’m look­ing for an au­di­ence as great as the pan­elists who are ap­pear­ing to dis­cuss cur­rent biotech events at the sum­mit. Bio­phar­ma ex­ecs look­ing to get in­to the con­ver­sa­tion are hearti­ly wel­come. Plus, we have a beer and wine mix­er at the end, which should be fun.


It’s a good thing that we are near­ly squared away on Lon­don, be­cause af­ter a quick trip to Mu­nich for ES­MO, I’ll be head­ed out to Shang­hai for a 2-day event we’re man­ag­ing with our part­ners in Chi­na, Pharm­Cube: US-Chi­na Bio­phar­ma In­no­va­tion & In­vest­ment Sum­mit. We’re still bring­ing to­geth­er the pan­els for this, but we have head­line events planned with en­tre­pre­neur Saman­tha Du, CEO of Zai Labs, Vivek Ra­maswamy from Roivant, John Oyler, the CEO at BeiGene, Jonathan Wang from Or­biMed Asia and Fa­heem Has­nain, co-founder and ex­ec­u­tive chair­man of Gos­samer, who you may re­call arranged the $7.2 bil­lion sale of Re­cep­tos to Cel­gene and re­cent­ly raised $330 mil­lion for his new ven­ture. 

Plus, we have lots and lots more ex­ecs who will be join­ing us.

We’re go­ing to be talk­ing deals, dol­lars and ren­min­bi at a cru­cial in­ter­sec­tion for US, Chi­nese and Eu­ro­pean play­ers. So why are we ask­ing you to join us? By in­ter­min­gling key play­ers on both sides of the Pa­cif­ic — as well as from Eu­rope — we’d like to spark some new talks on col­lab­o­ra­tions, de­vel­op­ment deals and fi­nanc­ing op­por­tu­ni­ties. Chi­na’s fast-grow­ing in­dus­try is chang­ing every­thing about the glob­al in­dus­try, and this is the time to ful­ly ex­plore it and make some con­nec­tions.

Fi­nal­ly, I’ll be head­ed down to Aus­tralia to keynote the an­nu­al Aus­Biotech gath­er­ing, which I’m re­al­ly look­ing for­ward to. And then I plan to sleep on the en­tire trip back to Ver­mont.

You may have no­ticed that our mot­to here is End­points News: The bio­phar­ma world is here. We weren’t kid­ding around.

Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.

Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi and DN­Di aim to elim­i­nate sleep­ing sick­ness in Africa with promis­ing Ph II/III re­sults for new drug

The Drugs for Neglected Diseases initiative (DNDi) and Sanofi today said that their potential sleeping sickness treatment saw success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole.

The potentially transformative treatment for sleeping sickness would mainly be targeted at African countries, according to data published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea, with the authors noting:

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Emily Leproust, Twist Bioscience CEO

Twist Bio­science’s 'fac­to­ry of the fu­ture' in Ore­gon could de­liv­er with com­pet­i­tive pric­ing, SVB Se­cu­ri­ties says

The synthetic DNA manufacturer Twist Bioscience has given a peek behind the curtain to several analysts into its “factory of the future” as well as insight into the cost structure, workflow and technology at the site.

The 110,000-square-foot manufacturing site in the city of Wilsonville, OR, just south of Portland, which was announced back in 2020, will double Twist’s production capacity and bring around 400 jobs to the area.

Digital render of CPI's Medicines Manufacturing Innovation Centre in Glasgow, Scotland (Image: uk-cpi.com)

CPI opens the doors to a new $100M+ man­u­fac­tur­ing fa­cil­i­ty in Scot­land

A manufacturing site that has received interest and investments from large pharma companies and the UK government is opening its doors in Scotland.

The manufacturer CPI (Centre for Process Innovation) has opened a new £88 million ($105 million) “Medicines Manufacturing Innovation Centre” in Glasgow, Scotland, to accelerate the development of manufacturing tech and solve longstanding challenges in medicine development and manufacturing.

Lex­i­con slams FDA over hear­ing de­nial fol­low­ing a CRL for its SGLT2 in­hibitor can­di­date

Lexicon Pharmaceutical is not giving up on its Type I diabetes candidate, despite FDA’s repeated rejections. This week the company laid out is argument again for a hearing on sotagliflozin in response to the FDA’s most recent denial.

The issue goes back to March 2019 when the FDA made very clear to Lexicon and its now departed partner Sanofi that it would not approve their application for a potential Type I diabetes drug because it does not appear to be safe.

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

After 24 years without confirming clinical benefit, the FDA announced Tuesday morning that Viatris (formed via Mylan and Pfizer’s Upjohn) has decided to withdraw a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said conducting a confirmatory study was not feasible.

Sulfamylon first won FDA’s accelerated nod in 1998 as a topical burn treatment, with the FDA noting that last December, Mylan told the agency that it wasn’t running the trial.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Pro­tect­ing its megablock­buster, Janssen chal­lenges Am­gen's Ste­lara biosim­i­lar ahead of planned 2023 launch

Johnson & Johnson unit Janssen on Wednesday sued Amgen over the company’s proposed biosimilar to its megablockbuster Stelara (ustekinumab), after Amgen said it was ready to launch next May or as soon as the FDA signs off on it.

If Amgen carries through with that plan, Janssen told the Delaware district court that the Thousand Oaks, CA-based company will infringe on at least two Janssen patents.